The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Plus, options traders eye NVAX; CMI surges to fresh peak; and CE looks to extend losing streak.

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus ...

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.74 which represents a decrease of $-0.18 or -1.81% from the prior close of $9.92. The stock opened at $9.9 and touched a low of ...

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa ...